DiaMedica Therapeutics (DiaMedica Therapeutics) Growth Rank : 0 (As of May. 24, 2024)

View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Growth Rank?

DiaMedica Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

DiaMedica Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website

https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Executives

Jan Stahlberg	10 percent owner	C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen	officer: CFO and Secretary	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill	10 percent owner	SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls	director, officer: President and CEO	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto	10 percent owner	394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke	officer: Chief Business Officer	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt	10 percent owner	C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von	10 percent owner	TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise	10 percent owner	C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves	officer: SVP Clinical Development Oper.	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305